Search Results - immunotherapy

59 Results

Sort By:

T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors

Abstract: Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely...

Published: 4/8/2024 | Inventor(s): Sanja Stevanovic, Christian Hinrichs

Keywords(s): CT83, Immunotherapy, Kita-Kyushu Lung Cancer Antigen, KK-LC-1, T-Cell Receptor, TCR, Testis

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Nanoparticle delivery of lung cancer therapeutic

Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in developed countries. Despite the availability of several synergistic, targeted therapy regiments, the 5-year survival rate for NSCLC is only 15%. The poor prognosis of NSCLS is due in part to limitations of current treatments, which do not trigger an immune...

Published: 5/22/2024 | Inventor(s): Dennis Klinman, Takashi Sato (Unable To Locate)

Keywords(s): Immunotherapy, Nanoparticle, Non-small cell lung cancer, NSCLC

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation

Abstract: Common methods of cancer therapy largely rely on either direct killing of cancer cells or activation of the host immune response to do so, but not both. A recently developed treatment of tumors uses an antibody/photo-absorber, Ab-IR700, with near infrared photoimmunotherapy (NIR-PIT), to selectively kill IR700-bound and NIR-light-exposed cancer...

Published: 4/8/2024 | Inventor(s): Hisataka Kobayashi, Peter Choyke

Keywords(s): antibody-IR700, Combination Therapy, Immunomodulators, Immunotherapy, Kobayashi, Metastasis, Near-Infrared Photo Immunotherapy, NIR-PIT, Photochemical, Tumor Inhibition

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Polymeric Delivery Platform for Therapeutics

Abstract: Drug delivery technologies have long claimed the ability to selectively deliver therapeutic cargo to target cells. Despite advances in nanomedicine and drug delivery systems, there are no targeted nanoscale drug delivery technologies on the market. Thus, there is still tremendous potential in improved therapeutic efficacy when targeted drug...

Published: 4/8/2024 | Inventor(s): David Stevens, Stephan Stern, Scott McNeil, Marina Dobrovolskaia

Keywords(s): Drug Delivery, Immunotherapy, Scavenger Receptor A1, SR-A1

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

Abstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan

Keywords(s): ANTIBODY, Immunotherapy, MESOTHELIN, therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy

Abstract: Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived...

Published: 4/8/2024 | Inventor(s): Steven Feldman, Steven Rosenberg, Ira Pastan

Keywords(s): CAR, Immunotherapy, MESOTHELIN, T-CELLS

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy

Abstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery

Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies

Abstract: T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T...

Published: 4/17/2024 | Inventor(s): Luca Gattinoni, Nicholas Restifo, Mario Roederer, Enrico Lugli

Keywords(s): anti-tumor activity, CANCER, Gattinoni, GSK-3beta, Immunotherapy, Infection, Stem Cell, T cell, WNT

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics

T cell Receptors Which Recognize Mutated EGFR

Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion...

Published: 4/8/2024 | Inventor(s): Kenichi Hanada, Chihao Zhao, Anna Pasetto, James Yang

Keywords(s): EGFR mutation, Epidermal Growth Factor Receptor, Hanada, Immunotherapy, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration

1 2 3 4 5 6